Supernus Pharmaceuticals (SUPN) EPS (Weighted Average and Diluted): 2011-2025
Historic EPS (Weighted Average and Diluted) for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$0.80.
- Supernus Pharmaceuticals' EPS (Weighted Average and Diluted) fell 215.94% to -$0.80 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.34, marking a year-over-year decrease of 131.71%. This contributed to the annual value of $1.32 for FY2024, which is 6500.00% up from last year.
- Latest data reveals that Supernus Pharmaceuticals reported EPS (Weighted Average and Diluted) of -$0.80 as of Q3 2025, which was down 300.00% from $0.40 recorded in Q2 2025.
- Supernus Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.69 during Q3 2024, with a 5-year trough of -$0.80 in Q3 2025.
- For the 3-year period, Supernus Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around $0.06, with its median value being $0.02 (2023).
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first surged by 1,900.00% in 2024, then crashed by 9,520.64% in 2025.
- Supernus Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarterly) stood at $0.04 in 2021, then surged by 950.00% to $0.42 in 2022, then crashed by 95.24% to $0.02 in 2023, then soared by 1,250.00% to $0.27 in 2024, then slumped by 215.94% to -$0.80 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.80 in Q3 2025, compared to $0.40 in Q2 2025 and -$0.21 in Q1 2025.